Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Featured Story

AstraZeneca's COVID-19 vaccine enters phase 2/3 clinical trial

Friday, May 22, 2020

Researchers at the University of Oxford have begun enrolling subjects in a phase 2/3 clinical trial of AstraZeneca-partnered COVID-19 vaccine AZD1222. The next stage of the program, which follows a 1,000-subject phase 1, is set to enroll 10,260 people in the U.K. to generate results to support the first shipments to customers in September.

April was 'worst month ever' for hospital finances: report

Thursday, May 21, 2020

By now, health systems around the country made it clear that April was a financial disaster in terms of lost revenues coupled with crippling supply expenses caused by the COVID-19 pandemic. Here's a look at just how bad was it across the industry.

FDA names 28 antibody tests to be taken off the market

Friday, May 22, 2020

The FDA named more than two dozen coronavirus antibody diagnostics that should be taken off the market weeks after the agency closed its open-door policy on COVID-19 blood tests and required developers to submit their products and data for review.

Kaiser Permanente wants to help employees safely return to their workspaces amid COVID-19. Here's how

Thursday, May 21, 2020

Kaiser Permanente released a playbook for offices to follow as they decide how to handle employees returning to the workplace amid the COVID-19 pandemic.

Inovio CEO on the COVID-19 vaccine race: Don’t count us out

Friday, May 22, 2020

As Inovio works to advance its DNA vaccine to fight COVID-19 into late-stage trials, it has been targeted by short sellers, or simply overlooked as bigger and better-funded rivals rapidly move forward with competing candidates. But Inovio CEO J. Joseph Kim remains confident that his company's long effort to develop DNA vaccines will pay off.

Biopharma roundup: Oxford-AstraZeneca vaccine enters large-scale trial; Avigan study presses on

Friday, May 22, 2020

AstraZeneca's Oxford University-partnered vaccine candidate is moving into a 10,000-subject clinical trial, as CEO Pascal Soriot called the U.S. government's $1 billion bet on the shot "absolutely worth it." A clinical trial of Fujifilm's Avigan continues despite reports of negative interim results. And more.

Healthcare roundup: Survey finds majority of docs aren't convinced states are ready to reopen

Thursday, May 21, 2020

FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry.

Physician pay was rising before COVID-19. Here's how much—and what MGMA expects for the future

Thursday, May 21, 2020

Doctors are taking a financial hit from the COVID-19 pandemic but overall physician compensation was on the rise in 2019. Compensation models will look different in the near future. Find out what trends could drive physician compensation higher going forward.

Coronavirus tests the value of artificial intelligence in medicine

Friday, May 22, 2020

The machine-learning programs scroll through millions of pieces of data to detect patterns that may be hard for clinicians to discern. Yet few of the algorithms have been rigorously tested against standard procedures.

ACOs seek info on Next Gen, Direct Contracting models amid COVID-19 pandemic

Friday, May 22, 2020

ACOs say the Trump administration must give answers on whether the Next Generation ACO Model will be around next year and what the Direct Contracting Model will look like.

Today's Rundown

Featured Story

Top Stories